ERTS Wealth Advisors’s AbbVie ABBV Stock Holding History

ERTS Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-776	Closed	-$72K	–	86
2018 Q4	$72K	Buy	+776	New	+$68.2K	0.05%	138

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ERTS Wealth Advisors's ABBV Position: Q1 2019 in Review

ERTS Wealth Advisors sold out of AbbVie (ABBV) in Q1 2019, closing a stake of 776 shares — an estimated $72K sold.

ERTS Wealth Advisors first reported a position in ABBV in Q4 2018 and held it in 1 quarter. The position peaked at $72K in Q4 2018. 2,033 funds tracked by Wall St. Rank hold ABBV as of Q1 2019.

ERTS Wealth Advisors reported no remaining AbbVie position as of Q1 2019 after selling out during the quarter.
ERTS Wealth Advisors sold 776 AbbVie shares in Q1 2019, an estimated $72K.
ERTS Wealth Advisors first reported a position in AbbVie in Q4 2018 and held it in 1 quarter.
ERTS Wealth Advisors's AbbVie position peaked at $72K in Q4 2018.
2,033 funds tracked by Wall St. Rank held AbbVie as of Q1 2019.

Based on ERTS Wealth Advisors's 13F filing for Q1 2019, filed 15 May 2019.